Lyell Immunopharma, INC Form 4 insider transactions

Veronica Sanchez Bulis, VP, Corporate Controller of Lyell Immunopharma, Inc., sold 621 shares of common stock on August 10, 2026 for $14.34 per share.

Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc., sold 131 shares of common stock on August 10, 2026 for $14.34 per share.

Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc., sold 89 shares of common stock on August 10, 2026 for $14.34 per share.

Lynn Seely, President and CEO and a Director of Lyell Immunopharma, Inc., sold 390 shares of common stock on August 10, 2026 for $14.34 per share.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 27, 2026.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 27, 2026.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 17, 2026.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 16, 2026.

Innovative Cellular Therapeutics Holdings Ltd. reports a transfer of 76,000 common shares as broker commission related to a license agreement, reducing its beneficial ownership.

Innovative Cellular Therapeutics Holdings Ltd, a director and 10% owner of Lyell Immunopharma, Inc., reported a transaction involving the transfer of 66,500 common shares.

CEO Lynn Seely sold 388 shares of Lyell Immunopharma to satisfy tax withholding obligations related to vested restricted stock units.

Chief Scientific Officer Gary K. Lee sold 130 shares of Lyell Immunopharma to satisfy tax withholding obligations.

Lyell Immunopharma Chief Operating Officer Stephen J. Hill sold 89 shares of common stock to satisfy tax withholding obligations.

Veronica Sanchez, VP and Corporate Controller of Lyell Immunopharma, sold 217 shares to cover tax obligations related to vested restricted stock units.

Director William J. Rieflin was granted 9,250 stock options in Lyell Immunopharma, Inc. as part of standard equity compensation.

Lyell Immunopharma director Sumant Ramachandra was granted 9,250 stock options as part of standard director compensation.

Director Elizabeth G. Nabel was granted 9,250 stock options in Lyell Immunopharma, Inc. as part of standard compensation.

Lyell Immunopharma director Richard Klausner was granted 9,250 stock options as part of his ongoing service to the company.

Lyell Immunopharma director Cathy Friedman was granted 9,250 stock options as part of standard equity compensation.

Lyell Immunopharma director Otis Brawley was granted 9,250 stock options as part of standard director compensation.

Director Mark Bachleda was granted 9,250 stock options in Lyell Immunopharma, Inc. as part of standard equity compensation.

Lyell Immunopharma's Chief Medical Officer, David Shook, reported a transaction involving the sale of 1,977 shares of common stock.

Lyell Immunopharma's Chief Financial and Business Officer, Smital Shah, was granted 140,000 stock options with a $25.5 exercise price, vesting over four years.

Lyell Immunopharma's President and CEO, Lynn Seely, sold 7,455 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, sold 1,236 shares of common stock on February 11, 2026, to cover tax withholding obligations related to vested restricted stock units.

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold 1,671 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Lyell Immunopharma's COO, Stephen J. Hill, reported the acquisition of 4,000 shares from performance-based RSUs, a tax-related sale of 109 shares, and a new option grant for 65,000 shares.

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, reported the acquisition of 4,000 common shares and 50,000 stock options, alongside a sale of 147 shares for tax purposes.

Lyell Immunopharma's President and CEO, Lynn Seely, reported the acquisition of 20,000 common shares from RSU vesting and 155,000 stock options, alongside a sale of 438 shares for tax purposes.

Lyell Immunopharma's General Counsel, Mark A. Meltz, received a grant of options to purchase 50,000 shares of common stock with a specified vesting schedule.